Table 2.

Duration of follow-up and incidence of renal and mortality end points during the study period (n=139)

CharacteristicData Available, n (%)Total Cohort (n=139)Did Not Develop Composite End Point (n=83)aDeveloped Composite End Point (n=56)a
Number of eGFR measurements, median (IQR)139 (100)22 (12–34)19 (11–29)27 (15–42)
Duration of renal functional follow-up (yr), median (IQR)b139 (100)4.7 (3.5–5.2)4.9 (4.1–5.2)4.1 (1.8–5.2)
Duration of study follow-up (yr), median (IQR)c139 (100)5.4 (4.7–5.7)5.4 (4.8–5.7)5.4 (4.4–5.7)
Slope of CKD-EPI eGFR (ml/min per BSA per yr), median (IQR)d129 (93)−0.9 (−2.3 to 0.5)0 (−1 to 1.6)−2.2 (−3.9 to −1.4)
≥40% decrease in CKD-EPI eGFR, n (%)139 (100)38 (27)0 (0)38 (68)
Doubling of serum creatinine, n (%)139 (100)14 (10)0 (0)14 (25)
Required RRT, n (%)139 (100)21 (15)0 (0)21 (38)
Death from any cause, n (%)139 (100)15 (11)0 (0)15 (27)
  • IQR, interquartile range; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; BSA, body surface area.

  • a Composite end point: ≥40% decrease in CKD-EPI eGFR, doubling of serum creatinine, RRT, or mortality.

  • b Duration between date of study enrollment and date of final eGFR determination. eGFR values subsequent to RRT initiation were excluded.

  • c Duration between date of study enrollment and date of last study follow-up or date of death.

  • d Slope of CKD-EPI eGFR was calculated only for individuals with three or more eGFR values over at least 1 year.